Logos Capital

Our mandate is to deliver best-in-class returns to our investors To do so, we thoroughly underwrite each investment, incorporating multiple layers of risk management to ensure our rationale, our “logos”, is perpetually aligned with those supporting us

The Logos team is composed of trained experts in the field of chemistry, engineering, biology, and data science We are committed to supporting true innovation through investing directly in companies pushing the boundaries of medical science and patient care Aligos Therapeutics Aligos is developing targeted, curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B virus, non-alcoholic steatohepatitis and hepatocellular carcinoma

ALX Oncology ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system

Annexon Biosciences Annexon Biosciences is a pioneer in developing C1q inhibitors designed to treat multiple complement-medicated autoimmune and neurodegenerative diseases

Athira Pharma Athira Pharma is a clinical stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer's disease and Parkinson's disease

Avidity Biosciences Avidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™) AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease

Black Diamonds Therapeutics Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule, Tumor-Agnostic Therapies C4 Therapeutics C4 Therapeutics is committed to transforming the treatment of cancer, neurological, and other important diseases with novel early stage therapies that eliminate disease-causing proteins C4’s approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients

Cogent Biosciences Cogent Biosciences is a biotechnology company developing therapies for genetically driven diseases

Dyne Therapeutics Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases

Flame Biosciences Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions

Gennao Bio Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology

InstilBio Instil Bio is a cell therapy company focused on solid tumors developing patient specific immunotherapies in oncology, allowing the patient’s own immune system to be harnessed to fight cancer

Kinnate Biopharma Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities Kinnate design and develop selective small molecules with the mission to provide the right drug to the right patient

Kymera Therapeutics Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases, advancing the field of targeted protein degradation by accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins

Nkarta Therapeutics Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies

Olema Pharmaceuticals Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development

Passage Bio Passage Bio is a genetic medicines company developing transformative therapies for the treatment of rare monogenic central nervous system diseases Pliant Therapeutics Pliant Therapeutics is a clinical stage biopharmaceutical company unraveling and targeting the key biological pathways driving fibrosis

Rain Therapeutics Rain Therapeutics Inc is a privately-held biotechnology company developing targeted therapies for patients with cancer

Repare Therapeutics Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics

Talaris Therapeutics Talaris is developing a single-dose cell therapy that seeks to produce durable immune tolerance to both an individual’s own tissues as well as donated organs from another individual

VelosBio VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer

Visen Pharmaceuticals VISEN Pharmaceuticals is committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market, and hoping to provide more Chinese patients quick access to the world's most advanced and reliable treatment solutions In 2018, VISEN Pharmaceuticals was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Investments), to develop and commercialize endocrinology therapies in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan

• Logos Capital 1 Letterman Drive Building C, Suite C3-350 San Francisco, CA 94129 This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Logos Global Management LP (“Logos Capital”) Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company In preparing the information contained in this website, Logos Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors Any views expressed on this website by Logos Capital were prepared based upon information, believed to be reliable, available to it at the time such views were written Logos Capital makes no guarantees as to their accuracy or completeness All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Logos Capital